Align Technology, Inc. (ALGN) reported a strong second quarter with both revenues and earnings sailing past the Zacks Consensus Estimates, on the back of its flagship product, Invisalign. Growth was boosted by increased patient visits and a growing interest among the teenage patient population.
In addition, contribution from Cadent helped Align to further penetrate the malocclusion market. The growth momentum is expected to sustain as scanner sales and opportunities in the digital dentistry and restorative markets rise.
The company's focus on the international market, especially in Europe and China, is encouraging. Rising earnings estimates and a product with great appeal and untapped potential, in the malocclusion market make us optimistic about Align. Accordingly, we upgrade the stock to Outperform.